What it sells
Utilizing monogenic disorders to inform and solve highly complex…
Business model breakdown
Workflow: what inputs become what output?
Preclinical and clinical development of precision drugs for rare neurodegenerative disease, starting with Batten disease and targeting palmitoylation/synaptic biology.
Economics: what it saves and how it charges
UnverifiedPre-revenue therapeutics developer; value would come from drug approval, licensing or partnership (site has Investors and Partners sections).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.